iNtRON Biotechnology (XKRX:048530) ROCE % : -6.73% (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is iNtRON Biotechnology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. iNtRON Biotechnology's annualized ROCE % for the quarter that ended in Dec. 2024 was -6.73%.

iNtRON Biotechnology ROCE % Historical Data

The historical data trend for iNtRON Biotechnology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iNtRON Biotechnology ROCE % Chart

iNtRON Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

21.18

11.74

10.33

-7.67

-3.26

iNtRON Biotechnology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-9.93	-3.22	-4.93	-5.75	-6.73

iNtRON Biotechnology ROCE % Calculation

iNtRON Biotechnology's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-2982.467	/	( ( (98614.591 - 785.968)	+	(86374.616 - 1338.101) )	/ 2 )
	=	-2982.467	/	( (97828.623	+	85036.515)	/ 2 )
	=	-2982.467	/	91432.569
	=	-3.26 %

iNtRON Biotechnology's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-5880.832	/	( ( (90966.449 - 1117.67)	+	(86374.616 - 1338.101) )	/ 2 )
	=	-5880.832	/	( ( 89848.779	+	85036.515 )	/ 2 )
	=	-5880.832	/	87442.647
	=	-6.73 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

iNtRON Biotechnology (XKRX:048530) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

iNtRON Biotechnology ROCE % Related Terms

Thank you for viewing the detailed overview of iNtRON Biotechnology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

iNtRON Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iNtRON Biotechnology Inc (XKRX:048530) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

137, Sagimakgol-ro, Jungwon-gu, Gyeonggi-do, Seongnam-si, KOR

Website

http://www.intron.co.kr

iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business.

iNtRON Biotechnology Headlines

No Headlines